« Previous
Next »
Gastroenterology
Volume 138, Issue 1
, Pages 266-274
, January 2010
The β3-Adrenoceptor Agonist GW427353 (Solabegron) Decreases Excitability of Human Enteric Neurons via Release of Somatostatin
References
- . Integration of gut function by sympathetic reflexes. Baillieres Clin Gastroenterol. 1988;2:45–62
- . Presynaptic inhibition at mammalian peripheral synapse?. Nature. 1974;250:430–431
- . Mechanism of synaptic inhibition by noradrenaline acting at alpha 2-adrenoceptors. Proc R Soc Lond B Biol Sci. 1988;234:85–114
- Post- and presynaptic effects of norepinephrine in guinea-pig colonic submucous plexus. Neurogastroenterol Motil. 1998;10:123–130
- Functional evidence of atypical β3-adrenoceptors in the human colon using the β3-selective adrenoceptor antagonist, SR 59230A. Br J Pharmacol. 1996;117:1374–1376
- In vitro inhibition of human colonic motility with SR 59119A and SR 59104A: evidence of a β3-adrenoceptor-mediated effect. Eur J Pharmacol. 1998;353:281–287
- Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology. 2007;133:175–183
- Distribution of β-3-adrenoceptor mRNA in human tissues. Eur J Pharmacol. 1995;289:223–228
- Somatostatin is expressed and secreted by human adipose tissue upon infection and inflammation. J Clin Endocrinol Metab. 2004;89:4833–4839
- Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2008;20(Suppl 2):131–132(abstract)
- Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am J Physiol. 2008;294:G1114–G1119
- Hydrogen sulfide is a novel prosecretory neuromodulator in the guinea-pig and human colon. Gastroenterology. 2006;131:1542–1552
- . Multisite optical recording of excitability in the enteric nervous system. Neurogastroenterol Motil. 1999;11:393–402
- Serotonin excites neurons in the human submucous plexus via 5-HT3 receptors. Gastroenterology. 2005;128:1317–1326
- Cutting-edge technology; III, imaging and the gastrointestinal tract: mapping the human enteric nervous system. Am J Physiol. 2002;282:G919–G925
- Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J Physiol. 2007;583:731–742
- . PGP 9.5—a new marker for vertebrate neurons and neuroendocrine cells. Brain Res. 1983;278:224–228
- . Degeneration of sympathetic nerves in vitro and development of smooth muscle supersensitivity to noradrenaline. J Physiol. 1972;221:71–84
- . Somatostatin increases an inwardly rectifying potassium conductance in guinea-pig submucous plexus neurones. J Physiol. 1987;390:335–355
- Beta(beta)3-adrenergic receptors in human pancreatic islet and duodenal somatostatin neuroendocrine cells. Aliment Pharmacol Ther. 2000;14:579–585
- . Effects of two beta 3-adrenoceptor agonists, SR 58611A and BRL 37344, and of salbutamol on cholinergic and NANC neural contraction in guinea-pig main bronchi in vitro. Br J Pharmacol. 1993;110:1311–1316
- . Identification and characterization of glucoresponsive neurons in the enteric nervous system. Neuroscience. 1999;19:10305–10317
- . TNF-alpha hyperpolarizes membrane potential and potentiates the response to nicotinic receptor stimulation in cultured rat myenteric neurones. Acta Physiol Scand. 2004;181:13–22
- Effect of CL316,243, a highly specific beta(3)-adrenoceptor agonist, on lipolysis of epididymal, mesenteric and subcutaneous adipocytes in rats. Endocr J. 1997;44:181–185
- . Innervation of submucosal adipocytes in the human colon. Neurosci Lett. 2007;428:7–10
- Somatostatin sst(2) receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology. 2001;121:358–369
- The beta(3)-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. Neurogastroenterol Motil. 2008;20:1030–1041
Conflicts of interest K.L. is an employee of GlaxoSmithKline, UK. S.C. and O.I.K. were employees of GSK at the time of the experiments. The remaining authors have no conflicts to disclose.
Funding This study has been in part supported by a research grant from GlaxoSmithKline.
PII: S0016-5085(09)01696-5
doi: 10.1053/j.gastro.2009.09.046
© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Gastroenterology
Volume 138, Issue 1
, Pages 266-274
, January 2010

